AroCell launches new website

Udgivet den 01-02-2019  |  kl. 12:32  |  

Today AroCell is launching its new website. The goal with the new website is to facilitate for our customers, business partner, and investors to find relevant information about AroCell.

The website (arocell.com) informs about precision monitoring in cancer care and the potential clinical utility of measuring the concentration of TK1 during cancer treatment. Thymidine kinase 1 (TK1) is a potential biomarker during cancer treatment.  The determination of the TK1 concentration in serum is simple using AroCell TK 210 ELISA, by using a blood sample from the patient, making timely decisions possible during treatment of cancer patients.

"Communicating with our customers, business partners, shareholders and investors is important for AroCell and our web is our major channel for this communication. I'm very pleased how the new website facilitates for our stakeholders to find relevant information about AroCell, our way forward and our product TK210 ELISA" says Michael Brobjer, CEO of AroCell.

The new website is designed with user-friendly navigation in mind, helping stakeholders to easy navigate through the site and find relevant information. The web has also got a face lift and a new fresh look.

For more information:
Michael Brobjer, CEO
Telephone: +46(0)18 50 30 20
E-mail: michael.brobjer@arocell.com

This information was submitted for publication through the agency of Michael Brobjer, February 1, 2019 at 13:30 hours.

About AroCell

AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210™ ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90.
For more information; www.arocell.com

 

Attachment

New website launched 20190201_EN

\Hugin

Udgivet af: NPinvestordk

Seneste nyheder

17:56 Europa/lukning: Vigtigt indeks rammer rekord efter ni grønne dage på stribe
17:38 Stort finanshus ser aktiefesten fortsætte i USA
17:06 Onsdagens obligationer: Afdæmpede inflationstal fra USA sendte renterne ned
17:05 Onsdagens aktier: Ambu tog tigerspring og sendte C25 tæt på rekord
16:03 Britisk modehus falder efter afdæmpet prognose: Ser udfordrende første halvår
15:52 KORR: Godt inflationsnyt fra USA: Holder liv i håbet om rentenedsættelser
15:41 USA/åbning: Rekordjagten skydes ind efter afdæmpet inflationsrapport
15:08 Valuta: Skuffende detailsalg og afdæmpet inflation presser dollar
14:48 USA/tendens: Stigninger i sigte oven på afdæmpet inflationsrapport
14:40 Godt inflationsnyt fra USA: Holder liv i håbet om rentenedsættelser
14:33 Amerikansk detailsalg skuffer
13:59 Lån & Spar med pæn vækst i centrale indtægtsposter men nedskrivninger trækker ned
13:36 Stigende renter rammer Jeudan - fastholder forventningerne
13:30 Novo: Udviklingsdirektør sælger aktier for over 8 mio. kr.
13:19 Novo hamstrer medarbejdere: Intern kantine-app er blandt de mest populære hos Appstore
12:59 Europa/aktier: Stoxx 600 på vej mod ni grønne dage på stribe - Ambu stiger mest
12:34 Rockwools endelige regnskab er på linje med foreløbige tal fra starten af maj
12:25 Obligationer/middag: Pænt rentefald inden amerikanske inflationstal svinger taktstokken
12:21 Amerikansk aktiemani trækker tråde til Danmark: Shortede aktier går til vejrs
12:00 FLSmidth-aktien vendt rundt på opløftende meldinger om Mining-divisionen